Cited by 114Gastrointestinal motility and disordersDrug Transport and Resistance MechanismsDrug Solubulity and Delivery Systems

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study: Randomised clinical trial: the ASBT/IBAT inhibitor A3309 in constipation

Simrén, M., Bajor, A., Gillberg, P.-G., Rudling, M., Abrahamsson, H.·2011·Alimentary Pharmacology & Therapeutics

DOI 10.1111/j.1365-2036.2011.04675.x

Open this paper in CoChat — free account

Abstract

BACKGROUND: One half of patients with constipation are not satisfied with available therapies, hence there is a need for more effective and well-tolerated drugs. AIM: To evaluate the effects of a specific inhibitor of the Ileal Bile Acid Transporter (IBAT; syn apical sodium-dependent bile acid transporter; ASBT) in patients with chronic idiopathic constipation (CIC) with focus on safety, colonic transit and efficacy signals. METHODS: This was a single-centre, prospective, randomised, double-blind, placebo-controlled study with a dose-escalating design in patients with CIC. In addition to evaluation of conventional safety and tolerability parameters, (i) colonic transit time (CTT) was measured using radio-opaque markers, (ii) metabolic parameters [lipid profile, C4 (7α-hydroxy-4-cholesten-3-one) and FGF19 (Fibroblast Growth Factor 19)] were evaluated, and (iii) constipation parameters, such as changes in stool frequency and consistency, were analysed. RESULTS: Thirty patients were randomised into five dose-levels (range: 0.1-10 mg/day) or to placebo. All patients completed a 14-day treatment period, and the safety/tolerability analysis was favourable. A3309, present in picomolar concentrations in plasma, induced up to a three-fold increase in bile acid synthesis (C4) and a reduction of plasma FGF19, as well as reduction in total and LDL cholesterol. CTT was reduced in the highest dose groups; the main acceleration was identified in the left colon. Efficacy parameters showed trends for increased number of spontaneous bowel movements and improved stool consistency. CONCLUSIONS: Ileal Bile Acid Transporter inhibition is a novel mechanism for treatment of patients with chronic idiopathic constipation and has additional benefits of improving metabolic parameters (EudraCT 2008-003255-72).

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2011.04675.x

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.
O'Donnell, L. J. D., Virjee, J., & Heaton, K. (1990) · British medical journal · doi:10.1136/bmj.300.6722.439 · Cited by 537
An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking
Paré, P., Ferrazzi, S., Thompson, W., Irvine, E. J., & Rance, L. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05259.x · Cited by 445
Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man
Lundåsen, T., Gälman, C., Angelin, B., & Rudling, M. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01731.x · Cited by 403
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation
Johanson, J. F., Morton, D., Geenen, J., & Ueno, R. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01524.x · Cited by 331
Long-term results of surgery for chronic constipation
Nyam, D., Pemberton, J., Ilstrup, D., & Rath, D. M. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02050415 · Cited by 255
Efficacy of Linaclotide for Patients With Chronic Constipation
Lembo, A. J., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., Jeglinski, B. I., & Johnston, J. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.050 · Cited by 237
Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood
Gälman, C., Arvidsson, I., Angelin, B., & Rudling, M. (2003) · Journal of Lipid Research · doi:10.1194/jlr.d200043-jlr200 · Cited by 194
Gender Differences in Gut Transit Shown with a Newly Developed Radiological Procedure
Sadik, R., Abrahamsson, H., & Stotzer, P.-O. (2003) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520310000410 · Cited by 183 · cited 1×
“4 days).(17) The CTT was reduced in the highest dose groups from 4.”
Background
Bile acids: short and long term effects in the intestine
Bajor, A., Gillberg, P., & Abrahamsson, H. (2010) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521003702734 · Cited by 142

Show all 20 references

Sorted by citations

Bowel Disorders
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
American Gastroenterological Association Technical Review on Constipation
Bharucha, A. E., Pembérton, J. H., & Locke, G. R. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.10.028 · Cited by 924
American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 664
Management of functional constipation in children and adults
Vriesman, M. H., Koppen, I. J. N., Camilleri, M., Di Lorenzo, C., & Benninga, M. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0222-y · Cited by 457
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 415
Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades
Hofmann, A. F., & Hagey, L. R. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r049437 · Cited by 365
Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269
Increase in fecal primary bile acids and dysbiosis in patients with diarrhea‐predominant irritable bowel syndrome
Duboc, H., Rainteau, D., Rajca, S., Humbert, L., Farabos, D., Maubert, M., Grondin, V., Jouet, P., Bouhassira, D., Seksik, P., et al. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01893.x · Cited by 256
Intestinal absorption of bile acids in health and disease
Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215
Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS
Bajor, A., Törnblom, H., Rudling, M., Ung, K., & Simrén, M. (2014) · Gut · doi:10.1136/gutjnl-2013-305965 · Cited by 215
Constipation: Pathophysiology and Current Therapeutic Approaches
Sharma, A., & Rao, S. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_111 · Cited by 190
Role of gut microbiota in functional constipation
Zhang, S., Wang, R., Li, D., Zhao, L., & Zhu, L. (2021) · Gastroenterology Report · doi:10.1093/gastro/goab035 · Cited by 175
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
Nakajima, A., Seki, M., Taniguchi, S., Ohta, A., Gillberg, P.-G., Mattsson, J. P., & Camilleri, M. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30123-7 · Cited by 169
Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters
Anwer, M. S., & Stieger, B. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1367-0 · Cited by 156
New treatments and therapeutic targets for IBS and other functional bowel disorders
Simrén, M., & Tack, J. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0034-5 · Cited by 150
Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation
Wong, B. S., Camilleri, M., McKinzie, S., Burton, D., Graffner, H., & Zinsmeister, A. R. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.285 · Cited by 133
The SLC10 Carrier Family
Döring, B., Lütteke, T., Geyer, J., & Petzinger, E. (2012) · Current topics in membranes · doi:10.1016/b978-0-12-394316-3.00004-1 · Cited by 131
Effects of Ficus carica paste on loperamide-induced constipation in rats
Lee, H.-Y., Kim, J., Jeung, H.-W., Lee, C.-U., Kim, D., Li, B., Lee, G., Sung, M.-S., Ha, K.-C., Back, H., et al. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.12.001 · Cited by 106
Characteristics of functional bowel disorder patients: a cross‐sectional survey using the Rome III criteria
Ford, A. C., Bercik, P., Morgan, D. G., Bolino, C., Pintos‐Sanchez, M. I., & Moayyedi, P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12573 · Cited by 102
Solute carriers as drug targets: Current use, clinical trials and prospective
Rask‐Andersen, M., Masuram, S., Fredriksson, R., & Schiöth, H. B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.015 · Cited by 98
Guidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised Edition
Shin, J. E., Jung, H., Lee, T. H., Jo, Y., Lee, H., Song, K. H., Hong, S. N., Lim, H. C., Lee, S. J., Chung, S. S., et al. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15185 · Cited by 96
Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
Al-Dury, S., & Marschall, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00931 · Cited by 99
The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation
Graffner, H., Gillberg, P., Rikner, L., & Marschall, H. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13457 · Cited by 94
Elobixibat and its potential role in chronic idiopathic constipation
Acosta, A., & Camilleri, M. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14528269 · Cited by 91
Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis
Kamath, B. M., Stein, P., Houwen, R. H. J., & Verkade, H. J. (2020) · Liver International · doi:10.1111/liv.14553 · Cited by 88
Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis
Al-Dury, S., Wahlstrom, A. M., Wåhlin, S., Langedijk, J., Elferink, R. P. J. O., Ståhlman, M., & Marschall, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-25214-0 · Cited by 87
Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples
Vijayvargiya, P., Busciglio, I. A., Burton, D. D., Donato, L. J., Lueke, A. J., & Camilleri, M. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.06.039 · Cited by 84
Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
Newsome, P. N., Palmer, M., Freilich, B., Sheikh, M. Y., Sheikh, A., Sarles, H., Herring, R., Mantry, P., Kayali, Z., Hassanein, T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.024 · Cited by 80
An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: The apical sodium-dependent bile acid transporter (SLC10A2/ASBT)
Xiao, L., & Pan, G. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.02.001 · Cited by 79
Brain‐Gut Axis
Camilleri, M., & Lorenzo, C. D. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31823d34c3 · Cited by 75
Gastrointestinal dysmotility disorders in critically ill dogs and cats
Whitehead, K., Cortes, Y., & Eirmann, L. (2016) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12449 · Cited by 79
Chronic Constipation: a Review of Current Literature
Sbahi, H., & Cash, B. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0471-z · Cited by 56
Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial
Nakajima, A., Seki, M., & Taniguchi, S. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1383-5 · Cited by 65
Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges
Li, M., Wang, Q., Li, Y., Cao, S., Zhang, Y., Wang, Z., Liu, G., Li, J., & Gu, B. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107539 · Cited by 61
Specific inhibition of bile acid transport alters plasma lipids and GLP-1
Rudling, M. J., Camilleri, M., Graffner, H., Holst, J. J., & Rikner, L. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0070-9 · Cited by 62
An Update of Pharmacological Management in Children with Functional Constipation
de Geus, A., Koppen, I. J. N., Flint, R. B., Benninga, M. A., & Tabbers, M. M. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00563-0 · Cited by 70
New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond
Sinagra, E., Morreale, G. C., Mohammadian, G., Fusco, G., Guarnotta, V., Tomasello, G., Cappello, F., Rossi, F., Amvrosiadis, G., & Raimondo, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6593 · Cited by 64
Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial
Tiessen, R. G., Kennedy, C., Keller, B. T., Levin, N., Acevedo, L. M., Gedulin, B. R., van Vliet, A. A., Dorenbaum, A., & Palmer, M. (2018) · BMC Gastroenterology · doi:10.1186/s12876-017-0736-0 · Cited by 49
Elobixibat for the treatment of constipation
Chedid, V. G., Vijayvargiya, P., & Camilleri, M. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1522248 · Cited by 49
Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome
Camilleri, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.261 · Cited by 47
Evidence-Based Clinical Guidelines for Chronic Constipation 2023
Ihara, E., Manabe, N., Ohkubo, H., Ogasawara, N., Ogino, H., Kakimoto, K., Kanazawa, M., Kawahara, H., Kusano, C., Kuribayashi, S., et al. (2024) · Digestion · doi:10.1159/000540912 · Cited by 60
Understanding and treating refractory constipation
Bassotti, G., & Blandizzi, C. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i2.77 · Cited by 48
Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles
Zhang, B., Kuipers, F., de Boer, J. F., & Kuivenhoven, J. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010004 · Cited by 43
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment
Spiller, R. (2016) · F1000Research · doi:10.12688/f1000research.7992.1 · Cited by 38
Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment
Corsetti, M., Brown, S. R., Chiarioni, G., Dimidi, E., Dudding, T. C., Emmanuel, A. V., Fox, M. R., Ford, A. C., Giordano, P., Grossi, U., et al. (2021) · Neurogastroenterology & Motility · doi:10.1111/nmo.14070 · Cited by 40
Elobixibat for the treatment of constipation
Wong, B., & Camilleri, M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.753056 · Cited by 47
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.
Jadallah, K. A., Kullab, S. M., & Sanders, D. S. (2014) · PubMed Central · doi:10.3748/wjg.v20.i27.8898 · Cited by 38
Chronic constipation: new diagnostic and treatment approaches
Lacy, B. E., Levenick, J. M., & Crowell, M. D. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12443093 · Cited by 39
Evolution of substrate specificity for the bile salt transporter ASBT (SLC10A2)
Lionarons, D. A., Boyer, J. L., & Cai, S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m025726 · Cited by 36
Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial
Kumagai, Y., Amano, H., Sasaki, Y., Nakagawa, C., Maeda, M., Oikawa, I., & Furuie, H. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13698 · Cited by 36
Contributions of bile acids to gastrointestinal physiology as receptor agonists and modifiers of ion channels
Keely, S. J., Urso, A., Ilyaskin, A. V., Korbmacher, C., Bunnett, N. W., Poole, D. P., & Carbone, S. (2021) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00125.2021 · Cited by 37
The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease
Ehtezazi, T., Rahman, K., Davies, R., & Leach, A. G. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220071 · Cited by 37
Guidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised Edition
Shin, J. E., Jung, H., Lee, T. H., Jo, Y., Lee, H., Song, K. H., Hong, S. N., Lim, H. C., Lee, S. J., Chung, S. S., et al. (2016) · Korean Journal of Medicine · doi:10.3904/kjm.2016.91.2.114 · Cited by 34
Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
Matsui, M., Fukunishi, S., Nakano, T., Ueno, T., Higuchi, K., & Asai, A. (2021) · mBio · doi:10.1128/mbio.01155-21 · Cited by 35
Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Hegade, V. S., Jones, D. E., & Hirschfield, G. M. (2017) · Digestive Diseases · doi:10.1159/000450988 · Cited by 32
Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments
Müller-Lissner, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.773972 · Cited by 31
The Mexican consensus on chronic constipation
Remes-Troche, J. M., Coss‐Adame, E., López‐Colombo, A., Amieva‐Balmori, M., Sánchez, R. C., Guindic, L. C., Rendón, R. F., Escudero, O. G., Martínez, M. G., Chávez, M. E. I., et al. (2018) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2018.05.012 · Cited by 31
Efficacy and safety of prucalopride in adults and children with chronic constipation
Diederen, K., Mugie, S. M., & Benninga, M. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.996547 · Cited by 29
Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials
Valentin, N., Acosta, A. J., & Camilleri, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1025132 · Cited by 29
Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
Eswaran, S. L., Guentner, A. S., & Chey, W. D. (2014) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2014.20.2.141 · Cited by 29
Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation
Nakajima, A., Ishizaki, S., Matsuda, K. M., Kurosu, S., Taniguchi, S., Gillberg, P., Mattsson, J. P., Hasunuma, T., & Camilleri, M. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15800 · Cited by 32
Bile acids and FXR in functional gastrointestinal disorders
Mosińska, P., Szczepaniak, A., & Fichna, J. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.05.016 · Cited by 30
Review article: Elobixibat: a novel treatment for chronic constipation
Khanna, L., & Camilleri, M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16143 · Cited by 26
Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation
Miner, P. B. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1508450 · Cited by 24
Phase II drugs under clinical investigation for the treatment of chronic constipation
Mozaffari, S., Didari, T., Nikfar, S., & Abdollahi, M. R. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.932770 · Cited by 20
Novel diagnostics and therapy of colonic motor disorders
Dinning, P. G., & Scott, S. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.002 · Cited by 18
Evidence connecting old, new and neglected glucose‐lowering drugs to bile acid‐induced GLP ‐1 secretion: A review
Kårhus, M. L., Brønden, A., Sonne, D. P., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12946 · Cited by 20
Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review
Mosińska, P., Sałaga, M., & Fichna, J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1142532 · Cited by 17
Non-systemic Intestine-Targeted Drugs
Fyfe, M. C. T. (2016) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2015.10.001 · Cited by 17
Advancing treatment options for chronic idiopathic constipation
Quigley, E. M. M., & Neshatian, L. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1127356 · Cited by 16
Consenso mexicano sobre estreñimiento crónico
Remes-Troche, J. M., Coss‐Adame, E., López‐Colombo, A., Amieva‐Balmori, M., Sánchez, R. C., Guindic, L. C., Rendón, R. F., Escudero, O. G., Martínez, M. G., Chávez, M. E. I., et al. (2018) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2017.12.005 · Cited by 19
Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study
Kamei, D., Kamei, Y., Nagano, M., Mineshima, M., Nitta, K., & Tsuchiya, K. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-1179-6 · Cited by 16
New Options in Constipation Management
Davis, M. P., & Gamier, P. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0481-x · Cited by 16
New pharmacological treatment options for chronic constipation
Corsetti, M., & Tack, J. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.900543 · Cited by 15
Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study
Siebers, N., Palmer, M., Silberg, D. G., Jennings, L., Bliss, C. A., & Martin, P. T. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0429-7 · Cited by 15
Treatment for constipation: New and old pharmacological strategies
Lacy, B. E., Hussain, Z. H., & Mearin, F. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12335 · Cited by 14
Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies.
Hussain, Z. H., Everhart, K. K., & Lacy, B. E. (2015) · PubMed Central · Cited by 14
Pharmacotherapeutic advances for chronic idiopathic constipation in adults
Bassotti, G., Usai–Satta, P., Berti, G., Lai, M., Villanacci, V., & Bellini, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2150076 · Cited by 13
Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation
Rothstein, R. D., & Friedenberg, F. K. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.833605 · Cited by 13
Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation
Mosińska, P. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i24.7436 · Cited by 12
New pharmacological treatment options for irritable bowel syndrome with constipation
Nusrat, S., & Miner, P. B. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1105215 · Cited by 11
The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study
Tomie, A., Yoshida, N., Kugai, M., Hirose, R., Dohi, O., Inoue, K., Okuda, K., Motoyoshi, T., Fukumoto, K., Inagaki, Y., et al. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/9656040 · Cited by 11
Drug discovery approaches to irritable bowel syndrome
Hornby, P. J. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1049528 · Cited by 11
A novel class of apical sodium--dependent bile salt transporter inhibitors: 1-(2,4-bifluorophenyl)-7-dialkylamino-1,8-naphthyridine-3-carboxamides
Liu, H., Pang, G., Ren, J., Zhao, Y., & Wang, J. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.11.005 · Cited by 11
Emerging treatments for chronic constipation
Gudsoorkar, V. S., & Quigley, E. M. M. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.831068 · Cited by 10
Gastrointestinal motility and neurogastroenterology
Törnblom, H., Simrén, M., & Abrahamsson, H. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1027265 · Cited by 10
The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs
Савельева, Е. Е., Tyutrina, E. S., Nakanishi, T., Tamai, I., & Salmina, A. B. (2020) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20206603185 · Cited by 9
Motility disorders of the colon and rectum
Wald, A. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834d4f61 · Cited by 3
Efficacy of elobixibat as bowel preparation agent for colonoscopy: Prospective, randomized, multi‐center study
Yamaguchi, D., Hidaka, H., Matsunaga, T., Akutagawa, T., Tanaka, Y., Jubashi, A., Takeuchi, Y., Tsuruoka, N., Sakata, Y., Miyahara, K., et al. (2021) · Digestive Endoscopy · doi:10.1111/den.14010 · Cited by 8
Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study
Hishida, Y., Nagai, Y., Tsukiyama, H., Nakamura, Y., Nakagawa, T., Ishizaki, S., Tanaka, Y., & Sone, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02243-w · Cited by 9
Effects of Elobixibat, an Inhibitor of Ileal Bile Acid Transporter, on Glucose and Lipid Metabolism: A Single-arm Pilot Study in Patients with T2DM
Yoshinobu, S., Hasuzawa, N., Nagayama, A., Iwata, S., Yasuda, J., Tokubuchi, R., Kabashima, M., Gobaru, M., Hara, K., Murotani, K., et al. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.08.009 · Cited by 7
Targeting bile acids in the treatment of constipation
Maneerattanaporn, M., & Chey, W. D. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.11.63 · Cited by 6
Exploring Bile Acid Transporters As Key Players In Cancer Development And Treatment: Evidence From Preclinical And Clinical Studies.
Bintee, B., Banerjee, R., Hegde, M., Vishwa, R., Alqahtani, M., Abbas, M., Alqahtani, A., Rangan, L., Sethi, G., & Kunnumakkara, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217324 · Cited by 5
Motility disorders of the colon and rectum
Gras-Miralles, B., Magge, S., Bloom, A., & Lembo, A. J. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a80e7 · Cited by 5
Apple juice relieves loperamide-induced constipation in rats by downregulating the intestinal apical sodium-dependent bile acid transporter ASBT
Zhu, Q., Iwai, R., Okaguchi, T., Shirasaka, Y., & Tamai, I. (2023) · Food & Function · doi:10.1039/d3fo00510k · Cited by 5
Recent Advances in the Management of Difficult Constipation
Lacy, B. E., Levenick, J. M., & Crowell, M. D. (2012) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0269-1 · Cited by 5
The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study
Li, B., Hu, Y., Wang, G., & Liu, L. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00422-5 · Cited by 4
Constipación crónica. Conceptos actuales desde la fisiopatología hasta el tratamiento
García‐Zermeño, K. R. (2021) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/zrrj9030 · Cited by 4
Inhibitors of the Apical Sodium-Dependent Bile Acid Transporter (ASBT) as Promising Drugs
Савельева, Е. Е., Tyutrina, E. S., Nakanishi, T., Tamai, I., & Salmina, A. B. (2021) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750821010078 · Cited by 2
Irritable Bowel Syndrome
Videlock, E. J., & Chang, L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch75 · Cited by 2

Authors: Simrén, M., Bajor, A., Gillberg, P.-G., Rudling, M., & Abrahamsson, H.
Affiliations: University of Gothenburg (SE)
Albireo (Sweden) (SE)
Karolinska University Hospital (SE)
Corresponding author: Simrén, M.
ORCID: Simrén, M.
Bajor, A.
Rudling, M.
Venue: Alimentary Pharmacology & Therapeutics
Publisher: Wiley
Published: 2011-05-05
Volume: 34
Issue: 1
Pages: 41-50
ISSN: 0269-2813 (ISSN-L)
DOI: 10.1111/j.1365-2036.2011.04675.x
OpenAlex: W1826937932
Cited by: 114
References: 20
Citations by year: 2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 9 · 2020: 10 · 2019: 3 · 2018: 12 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 12 · 2013: 6 · 2012: 10
FWCI: 11.49
Type: journal article
Language: en
Open access: closed
Licence: doi.wiley.com/10.1002/tdm_license_1 (tdm, 1580 d)
Locations: Alimentary Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Danone
Kommunfullmäktige, Stockholms Stad
Karolinska Institutet
Vetenskapsrådet
Sahlgrenska Universitetssjukhuset
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Keywords: chronic idiopathic constipation, colonic transit time, bile acid synthesis, C4, FGF19, LDL cholesterol, stool frequency, stool consistency, drug safety and tolerability
MeSH terms: Adult, Aged, Chronic Disease, Colon, Constipation, Defecation, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Cholesterol, LDL, Male, Middle Aged, Placebo Effect, Treatment Outcome, Patient Satisfaction, Symporters, Organic Anion Transporters, Sodium-Dependent

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study: Randomised clinical trial: the ASBT/IBAT inhibitor A3309 in constipation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks